Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kento Umino, Shin-Ichiro Fujiwara, Shoko Ito, Kiyomi Mashima, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi & Yoshinobu Kanda. (2017) Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leukemia & Lymphoma 58:2, pages 316-323.
Read now
Read now
Articles from other publishers (19)
Yuko Shirouchi, Noriko Nishimura, Yuko Mishima, Yuko Ishihara, Hiroaki Asai, Mikako Tamba, Mitsuhito Hirano, Kei Hirano, Yukako Teramoto, Kikuaki Yoshida, Kengo Takeuchi, Takashi Terauchi & Dai Maruyama. (2023) Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy. Scientific Reports 13:1.
Crossref
Crossref
Noriyuki Mizutani, Yuko Goto-Koshino, Keigo Kurata, Aki Fujiwara-Igarashi, Masahiro Sakaguchi, Minoru Asada, Koichi Ohno & Hajime Tsujimoto. (2020) Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma. Veterinary Immunology and Immunopathology 225, pages 110054.
Crossref
Crossref
Pablo Mozas, Alfredo Rivas-Delgado, Andrea Rivero, Iván Dlouhy, Ferran Nadeu, Olga Balagué, Blanca González-Farré, Tycho Baumann, Eva Giné, Julio Delgado, Neus Villamor, Elías Campo, Patricia Pérez-Galán, Xavier Filella, Laura Magnano & Armando López-Guillermo. (2020) High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research 94, pages 106371.
Crossref
Crossref
Joel C. Wight, Geoffrey Chong, Andrew P. Grigg & Eliza A. Hawkes. (2018) Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Reviews 32:5, pages 400-415.
Crossref
Crossref
Ivan Dlouhy, Xavier Filella, Jordina Rovira, Laura Magnano, Alfredo Rivas-Delgado, Tycho Baumann, Alejandra Martínez-Trillos, Olga Balagué, Antonio Martínez, Blanca González-Farre, Kennosuke Karube, Eva Gine, Julio Delgado, Elías Campo & Armando López-Guillermo. (2017) High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research 59, pages 20-25.
Crossref
Crossref
Shu-Juan Zhou, Yong-Yong Ma, Yu Zhang, Sheng Luo, Li-Yuan Tang, Yi Chen, Lan Sun & Kang Yu. (2016) Peripheral blood lymphocyte/monocyte ratio following completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. Annals of Hematology 96:2, pages 237-243.
Crossref
Crossref
Qing Shi, Rong Shen, Chao-Fu Wang, Xing Fan, Ying Qian, Bin-Shen Ou-Yang, Yan Zhao, Christophe Leboeuf, Anne Janin, Shu Cheng, Li Wang & Wei-Li Zhao. (2017) Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. Mediators of Inflammation 2017, pages 1-9.
Crossref
Crossref
Yasumasa Sugita, Chikako Ohwada, Takeharu Kawaguchi, Tomoya Muto, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Masahiro Takeuchi, Emiko Sakaida, Naomi Shimizu, Hiroaki Tanaka, Daijiro Abe, Motoharu Fukazawa, Takeaki Sugawara, Nobuyuki Aotsuka, Kaichi Nishiwaki, Katsuhiro Shono, Hiroyuki Ebinuma, Kengo Fujimura, Hideaki Bujo, Koutaro Yokote & Chiaki Nakaseko. (2016) Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. Clinica Chimica Acta 463, pages 47-52.
Crossref
Crossref
Thomas E. Witzig, Matthew J. Maurer, Mary J. Stenson, Cristine Allmer, William Macon, Brian Link, Jerry A. Katzmann & Mamta Gupta. (2014) Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. American Journal of Hematology 89:4, pages 417-422.
Crossref
Crossref
Tetsuichi Yoshizato, Yasuhito Nannya, Yoichi Imai, Motoshi Ichikawa & Mineo Kurokawa. (2013) Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 410-416.
Crossref
Crossref
Ana Márquez, Cristina Lucía Dávila-Fajardo, Gema Robledo, José Luis Callejas Rubio, Enrique de Ramón Garrido, Francisco J. García-Hernández, Rocío González-León, Raquel Ríos-Fernández, José Cabeza Barrera, Ma. Francisca González-Escribano, Ma. Teresa Camps García, Ma. Jesús Castillo Palma, Ma. del Mar Ayala, Norberto Ortego-Centeno & Javier Martín. (2013) IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports 40:8, pages 4851-4856.
Crossref
Crossref
Yoko Hashimoto, Akihiko Yokohama, Akio Saitoh, Hirotaka Nakahashi, Kohtaro Toyama, Takeki Mitsui, Hiromi Koiso, Takayuki Saitoh, Hiroshi Handa, Hideki Uchiumi, Takahiro Jinbo, Kayoko Murayama, Morio Matsumoto, Morio Sawamura, Masamitsu Karasawa, Hirokazu Murakami, Junko Hirato, Yoshihisa Nojima, Masaru Kojima & Norifumi Tsukamoto. (2013) Prognostic Importance of the Soluble Form of IL-2 Receptor^|^alpha; (sIL-2R^|^alpha;) and its Relationship with Surface Expression of IL-2R^|^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases. Journal of Clinical and Experimental Hematopathology 53:3, pages 197-205.
Crossref
Crossref
Lev Shvidel, Andrei Braester, Osnat Bairey, Naomi Rahimi-Levene, Yair Herishanu, Tamar Tadmor, Abraham Klepfish, Rosa Ruchlemer, Mordechai Shtalrid, Alain Berrebi & Aaron Polliack. (2012) Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients. Annals of Hematology 91:10, pages 1597-1602.
Crossref
Crossref
Tomohiro Aoki, Takahiro Nishiyama, Nobuhiko Imahashi & Kunio Kitamura. (2011) Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. Annals of Hematology 91:3, pages 375-382.
Crossref
Crossref
Sonali M. Smith. (2011) sIL-2Rα + IL-2: fertilizer for tolerance. Blood 118:10, pages 2645-2646.
Crossref
Crossref
Zhi-Zhang Yang, Deanna M. Grote, Steven C. Ziesmer, Michelle K. Manske, Thomas E. Witzig, Anne J. Novak & Stephen M. Ansell. (2011) Soluble IL-2Rα facilitates IL-2–mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118:10, pages 2809-2820.
Crossref
Crossref
Seon A Jo, Sang-Hyun Hwang, Chulhun L. Chang, Shine Young Kim, Ho-Jin Shin, Joo Seop Chung, Mee Young Sol & Eun Yup Lee. (2010)
Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2R
α
) in Patients with Non-Hodgkin’s Lymphoma
. Annals of Laboratory Medicine 30:6, pages 600-605.
Crossref
Crossref
Toshiaki Morito, Megumu Fujihara, Hideki Asaoku, Akira Tari, Yasuharu Sato, Kouichi Ichimura, Takehiro Tanaka, Katsuyoshi Takata, Maiko Tamura & Tadashi Yoshino. (2009) Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Science 100:7, pages 1255-1260.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:4, pages 253-260.
Crossref
Crossref